These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 18006781)
1. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Liu W; Wu X; Zhang W; Montenegro RC; Fackenthal DL; Spitz JA; Huff LM; Innocenti F; Das S; Cook EH; Cox NJ; Bates SE; Ratain MJ Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6788-95. PubMed ID: 18006781 [TBL] [Abstract][Full Text] [Related]
2. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617 [TBL] [Abstract][Full Text] [Related]
3. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658 [TBL] [Abstract][Full Text] [Related]
4. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985 [TBL] [Abstract][Full Text] [Related]
5. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. John T; Liu G; Tsao MS Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292 [TBL] [Abstract][Full Text] [Related]
6. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740 [TBL] [Abstract][Full Text] [Related]
7. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Wong KK Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579 [TBL] [Abstract][Full Text] [Related]
8. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Liu W; Innocenti F; Wu MH; Desai AA; Dolan ME; Cook EH; Ratain MJ Cancer Res; 2005 Jan; 65(1):46-53. PubMed ID: 15665278 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856 [TBL] [Abstract][Full Text] [Related]
10. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Kancha RK; von Bubnoff N; Peschel C; Duyster J Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutations in small cell lung cancer. Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487 [TBL] [Abstract][Full Text] [Related]
13. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Yung TK; Chan KC; Mok TS; Tong J; To KF; Lo YM Clin Cancer Res; 2009 Mar; 15(6):2076-84. PubMed ID: 19276259 [TBL] [Abstract][Full Text] [Related]
14. Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1. Sueoka-Aragane N; Imai K; Komiya K; Sato A; Tomimasu R; Hisatomi T; Sakuragi T; Mitsuoka M; Hayashi S; Nakachi K; Sueoka E Cancer Sci; 2008 Jun; 99(6):1180-7. PubMed ID: 18422739 [TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. Mustea A; Sehouli J; Fabjani G; Koensgen D; Möbus V; Braicu EI; Pirvulescu C; Thomas A; Tong D; Zeillinger R Anticancer Res; 2007; 27(3B):1527-30. PubMed ID: 17595771 [TBL] [Abstract][Full Text] [Related]
17. Impact of EGFR mutation analysis in non-small cell lung cancer. Yamamoto H; Toyooka S; Mitsudomi T Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859 [TBL] [Abstract][Full Text] [Related]
18. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Sasaki H; Kawano O; Endo K; Yukiue H; Yano M; Fujii Y Oncol Rep; 2007 Feb; 17(2):319-23. PubMed ID: 17203167 [TBL] [Abstract][Full Text] [Related]
19. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375 [TBL] [Abstract][Full Text] [Related]